Azacyclic compounds
US-9296694-B2 · Mar 29, 2016 · US
Methods for the treatment of parkinson's disease psychosis using pimavanserin
US9757366B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9757366-B2 |
| Application number | US-201615246412-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2016 |
| Priority date | Nov 27, 2012 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for reducing caregiver burden during the treatment of Parkinson's disease psychosis patients comprising administering pimavanserin or a pharmaceutically acceptable salt thereof to a Parkinson's disease psychosis patient, wherein the reduction in caregiver burden is measured on the Caregiver Burden Scale. 2. The method of claim 1 , wherein the Caregiver Burden Scale is completed by the patent's attending caregiver. 3. The method of claim 1 , wherein the Caregiver Burden Scale is completed by a self-administered 22-item questionnaire. 4. The method of claim 1 , wherein pimavanserin tartrate salt is administered to the Parkinson's disease psychosis patient. 5. The method of claim 1 , wherein pimavanserin or pharmaceutically acceptable salt is administered orally. 6. The method of claim 1 , wherein pimavanserin or pharmaceutically acceptable salt, is administered to the patient in a daily dose of about 40 mg.
Assignees
Inventors
Classifications
8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine · CPC title
condensed with carbocyclic rings · CPC title
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
only substituted in position 1, e.g. propipocaine, diperodon · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9757366B2 cover?
- Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin.
- Who is the assignee on this patent?
- Acadia Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4468. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).